Skye Bioscience, Inc. General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Net Loss Per Share of Common Stock (Tables)

Net Loss Per Share of Common Stock (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Earnings Per Share [Abstract]

Schedule of basic and diluted net loss per share

		Year Ended December 31,
		2018				2017
Net loss		$	(19,194,236	)		$	(4,138,298	)
Weighted average common shares outstanding – basic and diluted			121,154,334				27,906,090
Net loss per share – basic and diluted		$	(0.16	)		$	(0.11	)

Schedule of anti-dilutive securities

		Three Months Ended June 30, (Unaudited)								Six Months Ended June 30, (Unaudited)
		2019				2018				2019				2018
Stock options			2,411,846				1,850,073				2,814,505				1,850,073
Unvested restricted stock			209,055				1,918,501				237,798				1,918,501
Common shares underlying convertible debt			-				-				11,722,222				-
Warrants			18,844,002				51,155,750				20,353,145				51,155,750

		Year Ended December 31,
		2018				2017
Stock options			3,600,073				1,130,000
Unvested restricted stock			1,543,501				1,050,000
Common shares underlying convertible debt			5,000,000				4,000,000
Common shares underlying convertible preferred stock			-				50,335,500
Warrants			53,130,750				11,649,500